Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Pharmaceuticals Major
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| PFE | Pfizer Inc. | 2.30% | 54.26 | 0.9% | $2601.90m | |
| JNJ | Johnson & Johnson | 1.43% | 159.34 | 0.7% | $1311.17m | |
| MRK | Merck & Co., Inc. | -0.77% | 73.32 | 0.7% | $1166.64m | |
| BMY | Bristol-Myers Squibb Co. | 1.61% | 56.30 | 1.0% | $773.14m | |
| LLY | Eli Lilly & Co. | -0.93% | 245.57 | 1.1% | $726.06m | |
| ABBV | AbbVie, Inc. | 1.72% | 118.88 | 1.9% | $593.69m | |
| AZN | AstraZeneca Plc | -1.02% | 54.23 | 1.0% | $295.20m | |
| NVS | Novartis AG | 0.06% | 80.00 | 0.2% | $175.98m | |
| GSK | GlaxoSmithKline Plc | -0.53% | 41.25 | 0.2% | $162.67m | |
| DRNA | Dicerna Pharmaceuticals, Inc. | 0.34% | 38.25 | 0.3% | $148.96m | |
| VTRS | Viatris, Inc. | 0.00% | 12.20 | 0.0% | $142.65m | |
| RPRX | Royalty Pharma Plc | -3.16% | 37.65 | 0.1% | $112.47m | |
| BFRI | Biofrontera, Inc. | -18.67% | 4.27 | 0.0% | $107.17m | |
| RGEN | Repligen Corp. | -2.21% | 262.88 | 6.7% | $105.50m | |
| NVO | Novo Nordisk A/S | 0.45% | 107.12 | 0.1% | $85.21m |
Company Profile
Cybin, Inc. is a biotechnology company that focuses on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. It operates through the following segments: Serenity Life and Natures Journey. The Serenity Life segment engages in the research and development of pharmaceutical and nutraceutical psilocybin products. The Natures Journey segment focuses on non-psychedelic medical mushroom nutraceutical products. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.